On demand therapy for Parkinson’s disease patients: Opportunities and choices

References

• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014 Apr 23-30;311(16):1670–1683.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009 May 26;72(21 Suppl 4):S1–136.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020 Feb 11;323(6):548–560.
   PubMed Web of Science ®Google Scholar
• Marsden CD, Parkes JD. “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296.
   PubMed Web of Science ®Google Scholar
• Chou KL, Stacy M, Simuni T, et al. The spectrum of “off” in Parkinson’s disease: what have we learned over 40 years? Parkinsonism Relat Disord. 2018 Jun;51:9–16.
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Levodopa therapy for Parkinson’s disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2015 Jan;30(1):64–72.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lennernas H. Irregular gastrointestinal drug absorption in Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):193–203.
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF, Isaacson SH, Pahwa R. Clinical implications of gastric complications on levodopa treatment in Parkinson’s disease. Parkinsonism Relat Disord. 2020Jul ;76:63–71.
   PubMed Web of Science ®Google Scholar
• Fasano A, Visanji NP, Liu LW, et al. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015 Jun;14(6):625–639.
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Hammerstad JP, et al. The “on-off” phenomenon in Parkinson’s disease. Relation to levodopa absorption and transport. N Engl J Med. 1984 Feb 23;310(8):483–488.
   PubMed Web of Science ®Google Scholar
• Dardiotis E, Tsouris Z, Mentis AA, et al. H. pylori and Parkinson’s disease: meta-analyses including clinical severity. Clin Neurol Neurosurg. 2018 Dec;175:16–24.
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001 May;16(3):448–458.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Antonini A, Barone P, et al. Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord. 2014 Feb;20(2):204–211.
   PubMed Web of Science ®Google Scholar
• Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain. 2000 Nov;123(Pt 11):2297–2305.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Violante M, Ospina-Garcia N, Davila-Avila NM, et al. Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson’s disease. Arq Neuropsiquiatr. 2018 Aug;76(8):517–521.
   PubMed Web of Science ®Google Scholar
• Matthews H, Stamford J, Saha R, et al. Exploring issues around wearing-off and quality of life: the OFF-PARK survey of people with Parkinson’s disease and their care partners. J Parkinsons Dis. 2015;5(3):533–539.
   PubMedGoogle Scholar
• Hechtner MC, Vogt T, Zollner Y, et al. Quality of life in Parkinson’s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord. 2014 Sep;20(9):969–974.
   PubMed Web of Science ®Google Scholar
• Levit A, Zebendon C, Walter L, et al. Communication gaps about OFF periods between physicians and patients with Parkinson’s disease: a patient-physician dialogue analysis. Res Rev Parkinsonism. 2019;9:3–8.
   Web of Science ®Google Scholar
• Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson’s disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord. 2005 Jun;20(6):726–733.
   PubMed Web of Science ®Google Scholar
• Chahine LM, Edison B, Daeschler M, et al. The most bothersome aspects of Off periods reported by individuals with Parkinson’s disease. Mov Disord Clin Pract. 2020 Apr;7(3):284–292.
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018 Sep;17(9):749–759.
   PubMed Web of Science ®Google Scholar
• Moldovan AS, Groiss SJ, Elben S, et al. The treatment of Parkinson’s disease with deep brain stimulation: current issues. Neural Regen Res. 2015 Jul;10(7):1018–1022.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11;66(7):983–995.
   PubMed Web of Science ®Google Scholar
• Kondo T, Mizuno Y. Japanese Istradefylline Study Group. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol. 2015 Mar-Apr;38(2):41–46.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Ellenbogen A, Khanna S, et al. Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease. Neuropsychiatr Dis Treat. 2018;14:839–845.
   PubMed Web of Science ®Google Scholar
• Factor SA. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology. 2004 Mar 23;62(6 Suppl 4):S12–7.
   PubMed Web of Science ®Google Scholar
• Carbone F, Djamshidian A, Seppi K, et al. Apomorphine for Parkinson’s disease: efficacy and safety of current and new formulations. CNS Drugs. 2019 Sep;33(9):905–918.
   PubMed Web of Science ®Google Scholar
• Apokyn® (apomorphine hydrochloride injection) prescribing information Louisville, KY: US WorldMeds, LLC; 2017 [2020 june 21]. Available from: https://www.apokyn.com/sites/all/themes/apokyn/content/resources/apokyn_pi.pdf
   Google Scholar
• Obering CD, Chen JJ, Swope DM. Update on apomorphine for the rapid treatment of hypomobility (“off”) episodes in Parkinson’s disease. Pharmacotherapy. 2006 Jun;26(6):840–852.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020 Feb;19(2):135–144.
   PubMed Web of Science ®Google Scholar
• Kynmobi™ (apomorphine hydrochloride) sublingual film (prescribing information) Marlborough, Massachusetts: Sunovion Pharmaceuticals Inc.; 2020 [2020 Jul 2]. Available from: https://www.kynmobi.com/Kynmobi-Prescribing-Information.pdf
   Google Scholar
• LeWitt PA, Hauser RA, Grosset DG, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson’s disease. Mov Disord. 2016 Sep;31(9):1356–1365.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Isaacson SH, Ellenbogen A, et al. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson’s disease. Parkinsonism Relat Disord. 2019 Jul;64:175–180.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019 Feb;18(2):145–154.
   PubMed Web of Science ®Google Scholar
• Farbman ES, Waters CH, LeWitt PA, et al. A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2020 Dec;81:144–150.
   PubMed Web of Science ®Google Scholar
• Grosset DG, Dhall R, Gurevich T, et al. Inhaled levodopa in Parkinson’s disease patients with OFF periods: a randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020 Feb;71:4–10.
   PubMed Web of Science ®Google Scholar
• Safirstein BE, Ellenbogen A, Zhao P, et al. Pharmacokinetics of inhaled levodopa administered with oral carbidopa in the fed state in patients with Parkinson’s disease. Clin Ther. 2020 Jun ;42(6):1034–1046.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Isaacson S, Clinch T, et al. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord. 2014 Nov;20(11):1171–1176.
   PubMed Web of Science ®Google Scholar
• Dewey, Jr RB Jr., Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001 Sep;58(9):1385–1392.
   PubMedGoogle Scholar
• Pfeiffer RF, Gutmann L, Hull KL Jr., et al. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007 Mar;13(2):93–100.
   PubMed Web of Science ®Google Scholar
• Isaacson S, Lew M, Ondo W, et al. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson’s disease. Mov Disord Clin Pract. 2017 Jan-Feb;4(1):78–83.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Ondo WG, Van Lunen B, et al. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating “off” episodes in advanced Parkinson disease. Clin Neuropharmacol. 2009 Mar-Apr;32(2):89–93.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Chaudhuri KR, Garcia Ruiz PJ, et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease–Clinical practice recommendations. Parkinsonism Relat Disord. 2015 Sep;21(9):1023–1030.
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology. 2004 Mar 23;62(6 Suppl 4):S8–11.
   PubMed Web of Science ®Google Scholar
• Itin C, Komargodski R, Domb AJ, et al. Controlled delivery of apomorphine through buccal mucosa, towards a noninvasive administration method in Parkinson's disease: a preclinical mechanistic study. J Pharm Sci. 2020Sep;109(9):2729–2734.
   Web of Science ®Google Scholar
• Deffond D, Durif F, Tournilhac M. Apomorphine in treatment of Parkinson’s disease: comparison between subcutaneous and sublingual routes. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):101–103.
   PubMed Web of Science ®Google Scholar
• Inbrija®(levodopa inhalation powder), for oral inhalation use (prescribing information) Ardsley, NY: Acorda Therapeutics, Inc.; 2020 2021 Jul 21 . Available from: https://www.inbrija.com/prescribing-information.pdf?webSyncID=48330992-c742-8651-1d67-6513ea9e50c1&sessionGUID=5c823318-2c7b-d6cc-05ba-3e4300b1c75b
   Google Scholar
• Lipp MM, Batycky R, Moore J, et al. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease. Sci Transl Med. 2016 Oct 12;8(360):360ra136.
   PubMed Web of Science ®Google Scholar
• Shpiner DS, Bette S, Di Luca DG, et al. CVT-301 for the treatment of Parkinson’s disease. Expert Rev Neurother. 2019Jul;19(7):603–611.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson’s disease. Mov Disord. 2016 Sep;31(9):1366–1372.
   PubMed Web of Science ®Google Scholar
• Patel AB, Jimenez-Shahed J. Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date. Neuropsychiatr Dis Treat. 2018;14:2955–2964.
   PubMed Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011 Oct;26(Suppl 3):S42–80.
   PubMed Web of Science ®Google Scholar